Pre-ASP (n = 1,353) | Post-ASP (n = 5,155) | |||
---|---|---|---|---|
Term | Frequency a | Co-occurrence b | Frequency a | Co-occurrence b |
ALT | 1,677 (32.5) | 0.491 | ||
AST | 1,740 (33.8) | 0.505 | ||
Administration | 282 (20.8) | 0.345 | 1,378 (26.7) | 0.422 |
Bacterial Test | 936 (18.2) | 0.307 | ||
CRP | 338 (25.0) | 0.400 | 2,457 (47.7) | 0.646 |
Caution | 420 (31.0) | 0.474 | 1,114 (21.6) | 0.355 |
Ceftriaxone | 975 (18.9) | 0.318 | ||
Continuation | 1,041 (20.2) | 0.336 | ||
Creatinine | 459 (33.9) | 0.507 | 2,258 (43.8) | 0.609 |
Decrease | 1,056 (20.5) | 0.340 | ||
Discontinuation | 946 (18.4) | 0.310 | ||
Dosage | 296 (21.9) | 0.359 | ||
Drugs | 428 (31.6) | 0.481 | 1,098 (21.3) | 0.351 |
eGFR | 366 (27.1) | 0.426 | 2,179 (42.3) | 0.594 |
Explanation | 378 (27.9) | 0.437 | ||
Fever | 1,044 (20.3) | 0.337 | ||
Guidance | 364 (26.9) | 0.424 | ||
Hospitalization | 1,014 (19.7) | 0.329 | ||
Initiation | 358 (26.5) | 0.419 | 1,270 (24.6) | 0.395 |
Laboratory Test | 482 (35.6) | 0.525 | 2,609 (50.6) | 0.672 |
Management Method | 281 (20.8) | 0.344 | ||
Med. Adherence | 353 (26.1) | 0.414 | ||
Med. Reconciliation | 310 (22.9) | 0.373 | 916 (17.8) | 0.302 |
Med. Taking | 276 (20.4) | 0.339 | 931 (18.1) | 0.306 |
Medicine | 370 (27.3) | 0.430 | ||
Modification | 315 (23.3) | 0.378 | 1,424 (27.6) | 0.433 |
Necessity | 618 (45.7) | 0.627 | 1,025 (19.9) | 0.332 |
Neutrophil | 1,543 (29.9) | 0.461 | ||
Oral Administration | 327 (24.2) | 0.389 | 1,344 (26.1) | 0.414 |
Particularly | 497 (36.7) | 0.537 | ||
Prescription | 384 (28.4) | 0.442 | 1,258 (24.4) | 0.392 |
Qualitative Test | 1,497 (29.0) | 0.450 | ||
Renal Function | 346 (25.6) | 0.407 | ||
Report | 266 (19.7) | 0.329 | ||
SBT/ABPC | 1,062 (20.6) | 0.342 | ||
Safety | 434 (32.1) | 0.486 | ||
Tablet | 387 (28.6) | 0.445 | 1,260 (24.4) | 0.393 |
Take | 333 (24.6) | 0.395 | 979 (19.0) | 0.319 |
Tend | 1,158 (22.5) | 0.367 | ||
Verification | 698 (51.6) | 0.681 | 2,124 (41.2) | 0.584 |
WBC | 2,113 (41.0) | 0.582 |